iso-Isopulegol is a stereoisomeric monoterpene alcohol in the isopulegol family and appears in the AromaForge archive mainly through citronellal-rich lemon eucalyptus profiles. The accessible live literature is strongest for identity, stereochemical status, occurrence in lemon-eucalyptus-type oils, and biocatalytic production studies rather than for iso-isomer-specific human pharmacology. AromaForge should therefore treat iso-isopulegol primarily as a chemistry and composition marker with honest gaps around standalone safety and efficacy evidence.
Aroma and practical use
- Use the recorded minty, cool, terpenic, fresh descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A PubMed-indexed 2006 study on decaying Eucalyptus citriodora leaf oil reported an oil composition dominated by citronellal, citronellol, and isoisopulegol at 11.9%.
A PubMed-indexed 2006 study on decaying Eucalyptus citriodora leaf oil reported an oil composition dominated by citronellal, citronellol, and isoisopulegol at 11.9%.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Local archive oil records place iso-isopulegol at about 3.5% in one lemon eucalyptus GC report and 8.51% in one eucalyptus citriodora profile, reinforcing its role as a meaningful but secondary citronellal-rich oil constituent.
Local archive oil records place iso-isopulegol at about 3.5% in one lemon eucalyptus GC report and 8.51% in one eucalyptus citriodora profile, reinforcing its role as a meaningful but secondary citronellal-rich oil constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2019 biocatalysis paper described a selective enzyme cascade for producing (-)-iso-isopulegol from citral.
A 2019 biocatalysis paper described a selective enzyme cascade for producing (-)-iso-isopulegol from citral.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo iso-isopulegol-specific public human safety monograph or constituent-level dermal limit was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Public pharmacology papers located in this pass were largely for isopulegol generically rather than the iso-isomer specifically, so they were not upgraded into direct constituent claims here.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
Cyclization product in citronellal-to-isopulegol chemistry
The 2019 enzyme-cascade paper shows iso-isopulegol can be produced selectively from citral in a designed biocatalytic sequence, supporting its mechanistic role as a defined monoterpene cyclization product.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No direct human clinical literature for iso-isopulegol was verified in this pass.
- Most accessible pharmacology is for isopulegol generically, not the iso-isomer specifically.
- Constituent-specific dermal safety limits or a robust toxicology dossier were not located.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.